Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 19/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508737 | 1.00 | SELE (0.61) | SELE | |
| SCHEMBL19508545 | 0.98 | SELE (0.58) | SELE | |
| SCHEMBL19508732 | 0.97 | SELE (0.61) | SELE | |
| SCHEMBL19508547 | 0.97 | SELE (0.61) | SELE | |
| SCHEMBL25877305 | 0.96 | SELE (0.58) | SELE | |
| SCHEMBL19508544 | 0.96 | SELE (0.56) | SELE | |
| SCHEMBL19508551 | 0.95 | SELE (0.58) | SELE | |
| SCHEMBL25446476 | 0.95 | SELE (0.56) | SELE | |
| SCHEMBL25565258 | 0.95 | SELE (0.54) | SELE | |
| SCHEMBL19508541 | 0.94 | SELE (0.53) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712446-B2 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | GLYCOMIMETICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11712446-B2 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | GLYCOMIMETICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230127765-A1 | COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4 | GLYCOMIMETICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230127765-A1 | COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4 | GLYCOMIMETICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3227310-B1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS INC (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | SELE 1/4885 |
| US-11712446-B2 | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof | SELE, SELL, SELP | SELE 1/4885 |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | SELE 2/4885 |
| US-20230127765-A1 | COMBINATION OF T-CELL CHECKPOINT INHIBITORS WITH INHIBITORS OF E-SELECTIN OR CXCR4, OR WITH HETEROBIFUNCTIONAL INHIBITORS OF BOTH E-SELECTIN AND CXCR4 | SELE, CD274, CXCR3 | SELE 1/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | SELE 2/4885 |
| US-20170305951-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.